Jon Jones' pre-UFC 235 tests still show trace amounts of Turinabol - Figure Four Online

-

Although he has been cleared to fight at Saturday's UFC 235, light heavyweight champion Jon Jones still has trace amounts of Turinabol in his system according to a Thursday report by MMAFighting.com.

According to their sources, samples collected by the Nevada Athletic Commission on February 14th and February 15 showed 40 picograms per milliliter and 20 picograms per milliliter, respectively. 

The findings weren't enough for the NAC to make any changes in licensing Jones for his Saturday title defense against Anthony Smith in Las Vegas as they feel the traces of the steroid are still of the long-term variety and not a new presence.

Jones and Turinabol have been linked since 2017 but the issues flared up in late-December when the promotion had to move UFC 232 to California from Las Vegas on a week's notice due to various amounts of picograms found in Jones' system between August and December 2018.

Because of the timing of UFC 232 around the holidays and the defense that the picograms were from a positive 2017 test, the UFC was concerned the NAC wouldn't license Jones in time for his fight against Alexander Gustafsson. Thus, they infamously moved the event to Los Angeles.

Since then, Jones had to agree to testing throughout the year from VADA, the California State Athletic Commission, and NAC testing in addition to USADA. In late-January, Jones had a lengthy hearing in front of the NAC to explain the whole situation.

As documented in the MMA Fighting piece linked above, test results have come back completely clean and then partially positive off and on since December.



https://ift.tt/2ILrdWR

Comments

Post a Comment

Popular posts from this blog

Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

-
Image
Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and
Read more

Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

-
Image
3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t
Read more

Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

-
Image
hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n
Read more